Your search matched 60 results
IBM Watson for Oncology | Blog
Originally built as a complement for a physician and not as a replacement, IBM Watson for Oncology launched a study to determine how closely the artificial intelligence computer and a panel of 12-15 multidisciplinary tumor board members could agree on treatment approaches.
Immuno-oncology is fundamentally changing what value means | In The Media
How will the pharma marketing, educational and service model adapt in response to redefined value in immuno-oncology?
Making the Most of Maturing Oncology Brands | In The Media
Our experts crafted a checklist for Pharmaceutical Executive that can be used to determine if there’s hidden vitality left in aging oncology brands and inspire outside-of-the-box, often low-investment solutions to grow the bottom line.
MDigitalLife (a division of the W20 Group) recently conducted an examination of specific cancer communities online.
Navicor | Agency
Full-service, oncology-focused advertising agency transforming products into brands and patients into survivors.
Betting Big on Cancer.com | Blog
This month, Janssen launched Cancer.com, aiming to create an online destination for all things oncology.
GSW and Biosector 2 Are Shortlisted for 2019 MM&M Awards | In The Media
GSW and Biosector 2 are shortlisted for 2019 MM&M Awards for our client work with Endo Pharmaceuticals and Novartis Oncology.
In 2014, the American Society of Clinical Oncology (ASCO) released a landmark report about the state of cancer care in America.
There's been a spike in oncology DTC advertising in recent years, thanks to new drugs and mechanisms of action – and Syneos Health™ has the research to prove it.
PATIENT PARTNERS IN ONCOLOGY | Perspectives
Noticing important shifts in the rules of engagement between industry and patient advocates, Syneos Health Public Relations Group conducted in-depth interviews with dozens of patient organizations in early 2015.
Future look: The Impact of Biosimilars on Oncology | In The Media
Ben Curtis and Katherine Seay, inVentiv Health Managed Markets comment on how strategies will adjust with the advent of biosimilars.
David Lennon, VP & Franchise Head for US Oncology at Novartis, showed the #efpphilly crowd where we’re at as an industry with technology and data and where our opportunities lie for greater collaboration.
During this year’s Digital Pharma East conference, Stephanie Katzman, a healthcare strategist at LinkedIn, announced that the number of HCPs had grown from 3.5 million last year to over 5 million in the US alone and over 9 million globally in 2015.
CANCERCON is the experience that you never knew you needed because who the hell thinks about cancer when you’re not eighty years old?
Live from Cannes Lions: 9 people living with cancer + 6 months in their homes and lives = a story that shows it is possible to find a new normal
Shortages of critical cancer-fighting drugs have impacted 83% of U.S. oncologists in the past six months.* Around the world, doctors are negotiating availability, access and funding for the infusions they most want to prescribe.
A daunting task for any doctor.
2017 has marked a major shift in the way pharmaceutical giant Novartis will be using and expanding innovative digital platforms to share major congress experiences, education and medical information with physicians.
It’s been mighty cold lately, hasn’t it?
Live from EFP ‘18: The closing session for eyeforpharma ’18 brought the story full circle.
GlaxoSmithKline announced that it will acquire Waltham, Massachusetts-based drug company Tesaro, which develops novel cancer treatments, for $5.1 billion cash.
Complementary and alternative medicines (CAM) are therapies that are not considered the standard of care for a medical condition, and they represent $30 billion per year in consumer spending.
A global alliance of 17 organizations, headed up by the American College of Sports Medicine (ACSM), published a report advising doctors to prescribe exercise to cancer patients.
With healthcare expenses always seemingly on the rise, if you had the opportunity to reduce healthcare costs in your company by $1,464 annually per employee would you?
Wearables have been all the rage over the past few years.
Well, readers, it is - - amazingly - - the last month of 2018.
No matter whether you were the lone staffer in your office or relaxing on a beach somewhere this past week, we’ve got the run down on the latest healthcare headlines—the good, the bad and the ugly—to help you get you back up to speed.
Virtually everyone in the world, in some way and at some point, will be touched by cancer.
One of our top 2017 Healthcare Trends, “Dr Batman and AI Robin” outlined the ways in which artificial intelligence is really starting to change the way diseases are assessed, diagnosed, and treated.
Responding to rampant criticism of rising drug prices, pharma giant Eli Lilly will begin selling an authorized generic of its preeminent insulin therapy, Humalog, at half-price.